An investigational KRAS-targeted peptide vaccine generated durable immune responses and demonstrated early potential to intercept pancreatic cancer development in high-risk patients.

Orzeyful is the first orexin-restoring therapy for NT1, backed by the phase 3 FirstLight and RadiantLight trials.

Craig Beavers, PharmD, discusses a new American College of Cardiology expert consensus decision pathway that shifts HFpEF management from ejection fraction alone toward phenotype-driven diagnosis and treatment.

Schwartz must immediately address a measles crisis that has reached a 35-year high in the US, as well as a growing Cyclospora outbreak

This article highlights the efficacy and safety data of denileukin diftitox-cxdl for the treatment of relapsed or refractory cutaneous T-cell lymphoma.

The findings point to persistent vaccine hesitancy and access gaps in the years since the COVID-19 pandemic, with authors calling for stronger clinician recommendations and school-based vaccination sites.